Surmodics logo

SurmodicsNASDAQ: SRDX

Profile

Sector:

Healthcare

Country:

United States

IPO:

04 March 1998

Next earnings report:

31 January 2025

Last dividends:

N/A

Next dividends:

N/A
$543.43 M
-21%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-10%vs. 3y high
80%vs. sector
-34%vs. 3y high
57%vs. sector

Price

after hours | Thu, 14 Nov 2024 22:41:49 GMT
$38.09-$0.08(-0.21%)

Dividend

No data over the past 3 years
$33.23 M$33.37 M
$33.23 M-$3.45 M

Analysts recommendations

Institutional Ownership

SRDX Latest News

SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
zacks.com12 November 2024 Sentiment: POSITIVE

SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.

Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
zacks.com07 November 2024 Sentiment: POSITIVE

SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
zacks.com06 November 2024 Sentiment: POSITIVE

SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.

SRDX Stock Down Despite FDA Clearance for Pounce XL System
zacks.com02 October 2024 Sentiment: POSITIVE

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.

Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
zacks.com05 September 2024 Sentiment: POSITIVE

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com15 August 2024 Sentiment: POSITIVE

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings
zacks.com31 July 2024 Sentiment: POSITIVE

Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com31 July 2024 Sentiment: POSITIVE

SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX
globenewswire.com08 July 2024 Sentiment: POSITIVE

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
prnewswire.com03 July 2024 Sentiment: NEGATIVE

NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.

  • 1(current)
  • 2
  • 3

What type of business is Surmodics?

Surmodics, Inc. - a leading provider of medical devices and diagnostic technologies for healthcare system companies. The main focus is on cardiovascular diseases. The company was founded in 1979. The headquarters is located in the state of Minnesota. Surmodics, Inc. operates in two reporting business segments: the Medical Device Division - designs, develops, and manufactures interventional medical devices, primarily balloons and catheters for the treatment of peripheral artery diseases, urology, and others. The In Vitro Diagnostics Division - produces and sells components for diagnostic immunoassays, molecular tests, biomedical research.

What sector is Surmodics in?

Surmodics is in the Healthcare sector

What industry is Surmodics in?

Surmodics is in the Medical Devices industry

What country is Surmodics from?

Surmodics is headquartered in United States

When did Surmodics go public?

Surmodics initial public offering (IPO) was on 04 March 1998

What is Surmodics website?

https://www.surmodics.com

Is Surmodics in the S&P 500?

No, Surmodics is not included in the S&P 500 index

Is Surmodics in the NASDAQ 100?

No, Surmodics is not included in the NASDAQ 100 index

Is Surmodics in the Dow Jones?

No, Surmodics is not included in the Dow Jones index

When was Surmodics the previous earnings report?

No data

When does Surmodics earnings report?

The next expected earnings date for Surmodics is 31 January 2025